NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.37 -0.01 (-0.01%) GOLD FUTURES
2,322.50 -1.70 (-0.07%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,422.94 -387.18 (-0.76%)
Quince Therapeutics, Inc. (QNCX)
After hours:
| Previous close | 0.9600 |
| Open | 0.9600 |
| Bid | 0.8803 x 100 |
| Ask | 0.9734 x 100 |
| Day's range | 0.9040 - 0.9900 |
| 52-week range | 0.8400 - 1.7400 |
| Volume | |
| Avg. volume | 71,490 |
| Market cap | 39.758M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 06, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 beginning at 1:30 p.m. Eastern Time.
- Business Wire
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., April 01, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
- Business Wire
Quince Therapeutics Launches Scientific Advisory Board
SOUTH SAN FRANCISCO, Calif., February 22, 2024--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the launch of a Scientific Advisory Board (SAB) comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice.
